Combination of insulin sensitizer MSDC-0600 with tyrosine kinase inhibitor
Important notice: You must inform your CML doctor or a qualified doctor before using this drug. The material presented here is for information purposes only; it is not a substitute for your physician’s guidance and care.
"Previous research has shown that targeting how cancer cells use nutrients such as glucose to survive, may open the door to promising new treatment opportunities.
The researchers for this study found that CML stem cells – the vital cells that drive the disease – used glucose to fuel their mitochondria, the energy powerhouse of the cell. By doing that, these stem cells were also arming themselves to evade current treatments.
To combat this, researchers successfully targeted the CML stem cells using a drug that stops glucose getting into their mitochondria. The same drug has been tested in other clinical trials for the treatment of type 2 diabetes and Alzheimer’s disease. The research team is now exploring the possibility of moving findings into a clinical trial to see if combining this drug with current CML treatments would benefit patients."
Exctract of Diabetes drug may offer new treatment hope for chronic myeloid leukaemia
Diabetes drug may offer new treatment hope for chronic myeloid leukaemia
August 17, 2023, University of Glasgow
New treatment hope for chronic myeloid leukaemia
August 17, 2023, The Hippocratic Post
Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells
August 17, 2023, Nature